96 related articles for article (PubMed ID: 15834449)
1. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
Zhang S; Liu P; Jiang S; Hong X; Xing H; Xu X
Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449
[TBL] [Abstract][Full Text] [Related]
2. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Wang B; Xu X; Wang X
Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
[TBL] [Abstract][Full Text] [Related]
3. Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients.
Jiang S; Venners SA; Hsu YH; Weinstock J; Wang B; Xing H; Wang X; Xu X
Am J Hypertens; 2016 May; 29(5):553-9. PubMed ID: 26304961
[TBL] [Abstract][Full Text] [Related]
4. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
Zhang S; Mao G; Zhang Y; Tang G; Wen Y; Hong X; Jiang S; Yu Y; Xu X
Clin Ther; 2005 Nov; 27(11):1774-84. PubMed ID: 16368448
[TBL] [Abstract][Full Text] [Related]
5. Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan.
Jiang S; Hsu YH; Venners SA; Zhang Y; Xing H; Wang X; Xu X
J Hypertens; 2011 May; 29(5):890-5. PubMed ID: 21346624
[TBL] [Abstract][Full Text] [Related]
6. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.
Chen G; Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Xing H; Wang B; Yu Y; Xu X
Methods Find Exp Clin Pharmacol; 2006; 28(1):19-24. PubMed ID: 16541193
[TBL] [Abstract][Full Text] [Related]
9. Drug interactions with irbesartan.
Marino MR; Vachharajani NN
Clin Pharmacokinet; 2001; 40(8):605-14. PubMed ID: 11523726
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
Marino MR; Langenbacher K; Ford NF; Uderman HD
J Clin Pharmacol; 1998 Mar; 38(3):246-55. PubMed ID: 9549663
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of irbesartan in man.
Chando TJ; Everett DW; Kahle AD; Starrett AM; Vachharajani N; Shyu WC; Kripalani KJ; Barbhaiya RH
Drug Metab Dispos; 1998 May; 26(5):408-17. PubMed ID: 9571222
[TBL] [Abstract][Full Text] [Related]
13. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
Davi H; Tronquet C; Miscoria G; Perrier L; DuPont P; Caix J; Simiand J; Berger Y
Drug Metab Dispos; 2000 Jan; 28(1):79-88. PubMed ID: 10611144
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan for hypertension.
Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
[No Abstract] [Full Text] [Related]
15. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.
Huang XH; Li J; Qiu FR; Xie HT; Huang JH; Li JC; Zheng QS
Eur J Drug Metab Pharmacokinet; 2006; 31(4):259-64. PubMed ID: 17315536
[TBL] [Abstract][Full Text] [Related]
16. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
Kotridis P; Kokkas B; Karamouzis M; Sakadamis G; Kanonidis I; Dadous G; Karantona C; Gouli O; Karadoumanis J; Papadopoulos PC; Papadopoulos CL
Blood Press; 2002; 11(2):91-4. PubMed ID: 12035877
[TBL] [Abstract][Full Text] [Related]
17. A look through the new therapeutic window: irbesartan.
Waeber B; Brunner HR
J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
19. Irbesartan treatment in hypertension.
Brown MJ
Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
[TBL] [Abstract][Full Text] [Related]
20. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
Anusha A; Narendar D; Krishna Murthy B; Goverdhan P
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):179-185. PubMed ID: 28386752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
